Session Information
Date: Saturday, October 6, 2018
Session Title: Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment
Session Time: 1:45pm-3:15pm
Location: Hall 3FG
Objective: To describe the characteristics of dopaminergic treatments in a large group of patients with advanced Parkinson’s Disease (APD) in which current non-invasive therapy (oral, transdermal patch) alone was no longer effective.
Background: Continuous intra-jejunal infusion of Levodopa Carbidopa Intestinal Gel (LCIG) is an effective advanced therapy in the treatment of APD associated with severe motor fluctuations with or without dyskinesias. This is the only available device-aided treatment (DAT) in our department.
Methods: We conducted a retrospective review of all patients tested in our department between June 2011 and May 2017. We analyzed the particularities of dopaminergic agents usage based on the last treatment recommendations and referral letters.
Results: We tested 107 patients with APD (52 men, 55 women) with an average age of 64.7±8.64 years (mean±SD) and an average disease duration of 11.2±4.6 years. The average treatment duration with Levodopa was 11±4.6 years with an average daily dose of 758.8±250.6 mg divided in 5±1 doses. Only 12 patients received extended-release Levodopa treatment. Most patients (88) had treatment also with dopamine agonists, namely Pramipexole in 35 cases (average dose 2.38±0.58 mg), Ropinirole in 25 patients (average dose 14.4 mg±5.2 mg) or Rotigotine patch in 28 cases (average dose 7.7±2.4 mg). The therapeutic scheme included Rasagiline in 71 cases, Amantadine in 35 cases and in 71 cases Entacapone (average dose 1011.3±238.8 mg). All patients had off periods with an average duration 4.76±1.1 hours daily and 71 patients also had 2.97±0.8 hours/day dyskinesias. Out of the 107 patients that were initially tested eventually 89 underwent PEG-J.
Conclusions: The usage of dopaminergic treatments in patients with APD was similar to that described in literature. Due to the relatively high number of patients that in the end did not received LCIG through PEG-J we strongly believe that testing should be done during hospital stays.
To cite this abstract in AMA style:
J. Szasz, V. Constantin, K. Orban-Kis, L. Bancu, D. Georgescu, J. Szederjesi, I. Mihaly, S. Szatmari. Characteristics of dopaminergic treatments in advanced Parkinson’s before levodopa-carbidopa intestinal gel infusion: Data from 107 tested patients [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/characteristics-of-dopaminergic-treatments-in-advanced-parkinsons-before-levodopa-carbidopa-intestinal-gel-infusion-data-from-107-tested-patients/. Accessed May 15, 2025.« Back to 2018 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/characteristics-of-dopaminergic-treatments-in-advanced-parkinsons-before-levodopa-carbidopa-intestinal-gel-infusion-data-from-107-tested-patients/